Followers | 186 |
Posts | 13699 |
Boards Moderated | 1 |
Alias Born | 02/08/2011 |
Tuesday, February 02, 2016 4:47:00 PM
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) saw a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 2,169,360 shares, a growth of 40.8% from the December 31st total of 1,540,359 shares, MarketBeat.com reports. Based on an average daily volume of 1,173,211 shares, the short-interest ratio is presently 1.8 days. Currently, 3.4% of the shares of the company are short sold.
Several equities research analysts have weighed in on the company. Cowen and Company downgraded Threshold Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, December 7th. Stifel Nicolaus downgraded Threshold Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, December 7th. Piper Jaffray downgraded Threshold Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Monday, December 7th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $14.00 price target on shares of Threshold Pharmaceuticals in a research report on Monday, October 5th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $13.50.
Shares of Threshold Pharmaceuticals (NASDAQ:THLD) opened at 0.32 on Friday. The stock’s 50 day moving average is $0.43 and its 200 day moving average is $3.18. The stock’s market capitalization is $22.87 million. Threshold Pharmaceuticals has a 1-year low of $0.29 and a 1-year high of $5.28.
http://www.emqtv.com/short-interest-in-threshold-pharmaceuticals-inc-thld-increases-by-40-8/178707/
Recent MTEM News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:21:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 09:18:03 PM
- Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update • GlobeNewswire Inc. • 05/15/2024 09:11:54 PM
- Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patien • GlobeNewswire Inc. • 04/09/2024 12:11:00 PM
- Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update • GlobeNewswire Inc. • 03/29/2024 12:21:08 PM
- Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement • GlobeNewswire Inc. • 03/28/2024 12:11:00 PM
- Molecular Templates, Inc. Provides Interim Update • GlobeNewswire Inc. • 03/04/2024 01:11:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/15/2024 01:39:50 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:45:31 PM
- Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/08/2024 10:55:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 10:49:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 10:34:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 10:32:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:04:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:13:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:12:59 PM
- Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update • GlobeNewswire Inc. • 11/13/2023 09:11:00 PM
- Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors • GlobeNewswire Inc. • 11/02/2023 08:11:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/01/2023 08:14:59 PM
- Molecular Templates to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 11/01/2023 08:12:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 10:46:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 10:46:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 10:46:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 10:45:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 10:45:38 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM